Rituximab in Treating Patients With Non-Hodgkin’s Lymphoma or Hodgkin’s Disease
Study Information
Alliance Study ID: NCCTG-987851
NCT Study ID (ClinicalTrials.gov): NCT00003849
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Thomas E. Witzig, MD
Status: COMPLETED
Study Description
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them.
PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have non-Hodgkin’s lymphoma or Hodgkin’s disease.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information